#Japan #Shinjuku, Tokyo #Keio University #AdipoSeeds #ASCL-PLC

Introduction

AdipoSeeds, a Tokyo-based venture emerging from Keio University, has recently made headlines by successfully securing funding to advance its transformative regenerative medicine projects. The company is dedicated to developing a groundbreaking product known as ASCL-PLC (Adipose-derived Stem Cell Line-derived Platelet Like Cells) from fat tissue, aimed at addressing critical healthcare challenges.

Financing Details

The latest funding round involves a capital increase through a third-party allotment, primarily backed by Sysmex Corporation and DCI Partners, managing the Daiwa-Nichitai Bio Venture No. 2 Investment Limited Partnership. This strategic investment is set to bolster AdipoSeeds' efforts in clinical research and product development, particularly in supporting innovative treatment solutions for issues such as intractable skin ulcers and platelet shortages.

Collaboration with Sysmex Corporation

In collaboration with Sysmex, AdipoSeeds plans to fuse its competence in regenerative medicine product development with Sysmex's extensive assets and expertise in specimen testing and cellular manufacturing. Such a partnership underscores a commitment to improving quality control and manufacturing efficiency, leading to enhanced product reliability in the regenerative medicine landscape.

Clinical Research Initiatives

AdipoSeeds is actively working on two main developmental projects:
1. Treatment for Intractable Skin Ulcers (Project Code: ADS-01): This initiative has received approval from Japan's Agency for Medical Research and Development (AMED) under its 2024 initiative to strengthen the drug venture ecosystem. The funding secured will expedite the start of Phase I/II clinical trials in Japan, promising a significant advancement in skin ulcer treatment.

2. Exploratory Clinical Research for Platelet Disorders (Project Code: ADS-02): Focusing on the safety of ASCL-PLC in human subjects, AdipoSeeds is preparing to commence exploratory clinical research in collaboration with Tokyo Science University. Following a positive review from the university’s specialized committee on regenerative medicine, the project aims to rapidly advance the application of these platelet-like cells in treating conditions such as thrombocytopenia.

Vision and Mission

AdipoSeeds envisions creating a new horizon in medical treatment by converting waste fat into safe, clinically applicable platelet products at a low cost. Their overarching goal is to address the imminent shortage of platelets, a growing global concern, particularly as populations age. By facilitating more affordable and safer therapeutic options, AdipoSeeds aspires to contribute meaningfully to the future of healthcare.

Additionally, the company is focused on advancing PRP (Platelet Rich Plasma) therapies, utilizing the healing properties of platelet growth factors and the receptors present on their membranes to develop innovative treatment methods that do not rely on traditional blood donations for platelet supplies.

Company Overview

Founded in July 2016, under the leadership of CEO Junji Fuwa, AdipoSeeds operates from the Keio University Medical School premises in Shinjuku, Tokyo. The company not only emphasizes medical product innovation but also advocates for sustainable practices in regenerative medicine.

Conclusion

With recent financial backing and dedicated research initiatives, AdipoSeeds is poised to make significant strides in regenerative medicine. By harnessing advanced technologies and collaborative efforts, the company aims to reshape the landscape of medical therapies and meet the urgent healthcare needs of society.